Taken together, these preclinical results, combined with recent phase I/II data demonstrating significant clinical responses in multiple solid tumors resistant to chemotherapy including advanced endometrial cancer, strongly support the design of clinical trials of Dato-DXd in patients with TROP2-expressing biologically aggressive endometrial cancer in progression after chemotherapy and ICIs. Here, TACSTD2 is linked to endometrial cancer.